Together with national partners and as part of a European regulatory network, the MEB is continuously responsible for the assessment and monitoring of authorised products for the entire lifecycle.
Synergy is pursued within these national and EU relationships:
- between scientific and clinical, toxicological and pharmaceutical expertise
- in the distribution of tasks
- in creating greater efficiency and public confidence in the system.
The contribution to the team effort of creating the European marketing authorisation and pharmacovigilance system is a key strategic priority for the MEB. The MEB actively contributes on a European level through participation in a large number of platforms both within the European Medicines Agency (EMA) and beyond.